Adlyfe Appoints Roxanne Duan as Vice President of Research

ROCKVILLE, MARYLAND, September 17, 2007 -- Adlyfe, a private company developing novel diagnostic testing technologies for early targets of amyloid diseases, announced today that it has appointed Roxanne Duan, Ph.D. as Vice President of Research. Dr. Duan will be responsible for overseeing the Adlyfe’s R&D efforts and will report directly to the Chief Executive Officer.

Duan comes to Adlyfe with nearly two decades of experience. Most recently, Dr. Duan served as Vice President of Research at Functional Genetics, Inc., where she focused on developing anti-infectious therapeutics, including those for Ebola, Smallpox, HIV and Influenza and building applications for the company's RHGP platform. Prior to Functional Genetics, Dr. Duan served as project leader of several clinical therapeutic candidates at Human Genome Sciences (HGS). In addition, she holds more than 20 issued patents in the area of protein therapeutics. She has also served as Principal Consultant, R. Duan & Associates and as President, CEO, and founder of Infinity Pharmaceuticals, Inc., which was formed to discover medicine for cancer using proteomics and RNA silencing technology.

Dr. Duan began her career as a Senior Research Fellow at the National Cancer Institute from 1992 to 1995 where she studied tumor suppressor genes. She received her B.Sc. in Pharmacy from National Taiwan University and her Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco and worked as a postdoctoral fellow at the Howard Hughes Medical Research Institute at the University of California, San Francisco.

Alan Rudolph, President and CEO of Adlyfe, said, “We are delighted that Roxanne has joined Adlyfe in this important new role. Her experience brings a critical skill set to our rapidly growing diagnostic product development activities. Her experience in this area will be instrumental our efforts to develop diagnostic assays for neurodegenerative diseases such as Alzheimer's disease. As the Company enters its next phase of growth, we are excited to have attracted a professional of Roxanne’s caliber to support our efforts to develop these novel diagnostics.”

Roxanne Duan commented, "I am excited to become a part of Adlyfe and to join their excellent research team. I look forward to contributing to the development of this truly novel test for the detection and amplification of amyloid proteins as early biomarkers of fatal brain diseases."

About Adlyfe

Adlyfe Inc. was established early in 2003 to develop novel technologies for blood testing for early targets of amyloid diseases. Adlyfe is developing a novel test for the detection and amplification of amyloid proteins as early biomarkers of fatal brain and amyloid diseases such as Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jacob disease, Huntington's disease, systemic amyloidosis, diabetes and other diseases.

The Company's novel technology is based on the synthesis of small peptide, or Pronucleon(TM) ligands, that are amino acid sequence matched to target amyloids of interest. Ligand sequences are selected based on regions of the target protein known to undergo conformational changes (structural changes in shape) associated with amyloid aggregation (and eventual amyloid plaque formation). These aggregates are associated with disease state progression in a number of brain-wasting and amyloid diseases.

Adlyfe, a privately-held corporation, was initially funded by the Defense Advanced Research Projects Agency (DARPA), the U.S. Army Medical Research and Materiel Command, the National Heart, Lung and Blood Institute, and Britain's Department for Environment, Food and Rural Affairs. More recently, Adlyfe raised additional funding with venture capital firms Canaan Venture Partners and Burrill Associates.

For More Information

Media:
Janine McCargo
1-646-536-7033
jmccargo@theruthgroup.com